Literature DB >> 10755396

Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group.

T M Wagner1, R Möslinger, G Langbauer, R Ahner, E Fleischmann, A Auterith, A Friedmann, T Helbich, C Zielinski, E Pittermann, M Seifert, P Oefner.   

Abstract

The intent of this study was to evaluate the effect that an awareness of being a BRCA1 or BRCA2 mutation carrier has on the attitude towards prophylactic surgery and on developing depression symptoms. Thirty-five families were selected on the basis of previously detected BRCA1 or 2 mutations and 90 family members were given the appropriate questionnaires. Prophylactic mastectomy (PM) was considered by 21% of the Austrian mutation carriers (29% affected and 8% non-affected carriers). The majority of affected and non-affected carriers expected PM to impair the quality of their life. Fifty per cent would undergo prophylactic oophorectomy (53% affected and 46% non-affected carriers). The self-rating depression scale indicated that following mutation result disclosure the depression scores of carriers decreased (40 baseline vs 38 after result disclosure, P = 0.3), whereas, for non-carriers, scores increased (36 baseline vs 40 after result disclosure, P = 0.05). We conclude that information about carrier status is not associated with increased depression symptoms in mutation carriers. In non-carriers, depression scores increased slightly, probably reflecting survivor guilt. The option of having PM was associated with a negative impact on the quality of life and was declined by the majority of Austrian mutation carriers.

Entities:  

Mesh:

Year:  2000        PMID: 10755396      PMCID: PMC2374490          DOI: 10.1054/bjoc.1999.1086

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  DNA-testing for Huntington's disease in The Netherlands: a retrospective study on psychosocial effects.

Authors:  A Tibben; M Vegter-van der Vlis; M I Skraastad; P G Frets; J J van der Kamp; M F Niermeijer; G J van Ommen; R A Roos; H G Rooijmans; D Stronks
Journal:  Am J Med Genet       Date:  1992-09-01

2.  Few psychological consequences of presymptomatic testing for Huntington disease.

Authors:  S Bundey
Journal:  Lancet       Date:  1997-01-04       Impact factor: 79.321

Review 3.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

Authors:  W Burke; M Daly; J Garber; J Botkin; M J Kahn; P Lynch; A McTiernan; K Offit; J Perlman; G Petersen; E Thomson; C Varricchio
Journal:  JAMA       Date:  1997-03-26       Impact factor: 56.272

4.  The influence of psychological distress on use of genetic testing for cancer risk.

Authors:  C Lerman; M D Schwartz; T H Lin; C Hughes; S Narod; H T Lynch
Journal:  J Consult Clin Psychol       Date:  1997-06

5.  Psychological responses to BRCA1 mutation testing: preliminary findings.

Authors:  R T Croyle; K R Smith; J R Botkin; B Baty; J Nash
Journal:  Health Psychol       Date:  1997-01       Impact factor: 4.267

6.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.

Authors:  C Lerman; S Narod; K Schulman; C Hughes; A Gomez-Caminero; G Bonney; K Gold; B Trock; D Main; J Lynch; C Fulmore; C Snyder; S J Lemon; T Conway; P Tonin; G Lenoir; H Lynch
Journal:  JAMA       Date:  1996-06-26       Impact factor: 56.272

7.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

Authors:  L C Hartmann; D J Schaid; J E Woods; T P Crotty; J L Myers; P G Arnold; P M Petty; T A Sellers; J L Johnson; S K McDonnell; M H Frost; R B Jenkins
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

Review 8.  The impact of breast cancer on sexuality, body image, and intimate relationships.

Authors:  L R Schover
Journal:  CA Cancer J Clin       Date:  1991 Mar-Apr       Impact factor: 508.702

9.  The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing.

Authors:  S Wiggins; P Whyte; M Huggins; S Adam; J Theilmann; M Bloch; S B Sheps; M T Schechter; M R Hayden
Journal:  N Engl J Med       Date:  1992-11-12       Impact factor: 91.245

10.  Self-selection in predictive testing for Huntington's disease.

Authors:  A M Codori; R Hanson; J Brandt
Journal:  Am J Med Genet       Date:  1994-09-15
View more
  17 in total

1.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

2.  Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications.

Authors:  Carrie Snyder
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

3.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

4.  Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery.

Authors:  Rachel Shapira; Erin Turbitt; Lori H Erby; Barbara B Biesecker; William M P Klein; Gillian W Hooker
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

5.  Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage.

Authors:  Allison W Kurian; Anne-Renee Hartman; Meredith A Mills; James M Ford; Bruce L Daniel; Sylvia K Plevritis
Journal:  Health Expect       Date:  2005-09       Impact factor: 3.377

6.  BRCA1/2 genetic testing uptake and psychosocial outcomes in men.

Authors:  Kristi D Graves; Rhoda Gatammah; Beth N Peshkin; Ayelet Krieger; Christy Gell; Heiddis B Valdimarsdottir; Marc D Schwartz
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

7.  Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.

Authors:  Brita Arver; Aina Haegermark; Ulla Platten; Annika Lindblom; Yvonne Brandberg
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

8.  Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer.

Authors:  Jon G Reichelt; Pål Møller; Ketil Heimdal; Alv A Dahl
Journal:  Fam Cancer       Date:  2008-01-25       Impact factor: 2.375

9.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

10.  Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation.

Authors:  Kelly A Metcalfe; Parviz Ghadirian; Barry Rosen; William Foulkes; Charmaine Kim-Sing; Andrea Eisen; Peter Ainsworth; Doug Horsman; Christine Maugard; Diane Provencher; André Robideaux; Dawna Gilchrist; Albert Chudley; Edmond G Lemire; Susan Armel; Amy Finch; Ping Sun; Steven A Narod
Journal:  Open Med       Date:  2007-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.